Pfizer/Merck KGaA’s Bavencio set for bladder cancer advantage after phase 3 winPfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their Share XPfizer/Merck KGaA’s Bavencio set for bladder cancer advantage after phase 3 winhttps://pharmaphorum.com/news/pfizer-merck-kgaas/
NHS patients to get easier access to MS pill after NICE rethinkPatients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped Share XNHS patients to get easier access to MS pill after NICE rethinkhttps://pharmaphorum.com/news/nhs-patients-to-get-easier-access-to-ms-pill-after-nice-rethink/
Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drugThe FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug Share XMerck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drughttps://pharmaphorum.com/news/merck-kgaa-nabs-fda-breakthrough-tag-for-met-targeting-lung-cancer-drug/
Tackling the remaining challenges of multiple sclerosisWith Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond Share XTackling the remaining challenges of multiple sclerosishttps://pharmaphorum.com/r-d/views-analysis-r-d/tackling-the-remaining-challenges-of-multiple-sclerosis/
Merck and Pfizer’s Bavencio approved for renal cell carcinomaMerck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta Share XMerck and Pfizer’s Bavencio approved for renal cell carcinomahttps://pharmaphorum.com/news/merck-and-pfizers-bavencio-approved-for-renal-cell-carcinoma/
German Merck shows new data backing BTK drug evobrutinib in MSGermany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor Share XGerman Merck shows new data backing BTK drug evobrutinib in MShttps://pharmaphorum.com/news/german-merck-shows-new-data-backing-btk-drug-evobrutinib-in-ms/
Merck KGaA signs another AI dealMerck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative Share XMerck KGaA signs another AI dealhttps://pharmaphorum.com/news/merck-kgaa-signs-another-ai-deal/
Merck KGaA admits to ‘challenging’ 2018, as currencies hit salesGermany’s Merck KGaA has described 2018 as a “challenging” year, which saw profits hit by currency headwinds and Share XMerck KGaA admits to ‘challenging’ 2018, as currencies hit saleshttps://pharmaphorum.com/news/merck-kgaa-admits-to-challenging-2018-as-currencies-hit-sales/
